These data raise the possibility that reversing the high-risk signature using IFN-γ/β-glucan may allow for an increase in the M1 macrophage population and enhance the anti-tumor efficiency of macrophages in MPE to improve anti-cancer therapy. The gene discussed is IFNG; the disease is cancer.